XALKORI (crizotinib) Patient Assistance Program
Don’t let the high cost of brand specialty ALK/ROS1-targeted lung cancer therapy disrupt your treatment. We help eligible patients access Xalkori (crizotinib) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Xalkori (crizotinib) is FDA-approved for ALK-positive or ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), ALK-positive anaplastic large cell lymphoma (ALCL) in pediatric and young adult patients, and unresectable, recurrent, or refractory inflammatory myofibroblastic tumor in pediatric and adult patients. It is an oral tyrosine kinase inhibitor.
- Without assistance, Xalkori costs commonly run approximately $20,000–$23,500 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Xalkori for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no generic Xalkori in the U.S. as of 2026. Newer ALK inhibitors with better efficacy and CNS penetration are now preferred for ALK-positive NSCLC: alectinib (Alecensa), brigatinib (Alunbrig), lorlatinib (Lorbrena), and ceritinib (Zykadia). Xalkori remains an option in specific settings and for ROS1-positive disease where lorlatinib and entrectinib are alternatives.
What Is Xalkori Prescription Assistance Program?
The Xalkori Prescription Assistance Program is a manufacturer-sponsored initiative that provides Xalkori at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for ALK-positive or ROS1-positive cancer patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology coordination, ALK/ROS1 genomic-testing documentation, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and re-certification.
Pharmacy Price Comparison
- Without assistance, Xalkori costs roughly $20,000–$23,500/month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$22,500 | Save substantially |
| CVS Pharmacy | ~$23,500 | Save substantially |
| Walmart | ~$20,500 | Save substantially |
| Costco | ~$20,200 | Save substantially |
Specialty Pharmacy | ~$21,000 | Save substantially |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Xalkori Prescription Program?
The Patient Assistance Program is free to apply for and provides Xalkori at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
The Patient Assistance Program is free to apply for and provides Xalkori at no medication cost if approved. Our $69.95/month service covers full advocacy.
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $20,000–$23,500 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Xalkori assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Xalkori Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Xalkori:
Xalkori (crizotinib) is a twice-daily oral tyrosine kinase inhibitor of ALK, ROS1, and MET kinases. It was the first FDA-approved ALK inhibitor (2011) for NSCLC patients harboring ALK gene rearrangements — establishing genotype-directed therapy in lung cancer.
How Xalkori Works:
Crizotinib is a targeted inhibitor that blocks the ATP-binding sites of ALK and ROS1 kinases, which are abnormally active in a small percentage of NSCLC patients and drive tumor growth. Blocking these constitutively active fusion kinases triggers rapid tumor regression in many individuals who test positive for these genetic rearrangements. However, most patients eventually develop resistance to the treatment, typically driven by specific mutations like G1202R. Because of this resistance and the need for better central nervous system penetration, newer-generation ALK inhibitors are now generally preferred over crizotinib for standard use.
Form and use:
Marketed under the brand name Xalkori, this medication is available in 200 mg and 250 mg capsules and is taken orally twice a day. The standard adult dosage is 250 mg twice daily, and it can be administered with or without food, while pediatric dosing is calculated based on body surface area. Patients must manage drug interactions carefully, as strong CYP3A inhibitors necessitate a reduction in the crizotinib dose. Conversely, strong CYP3A inducers can significantly lower the drug’s therapeutic levels and must be avoided entirely.
Generic availability:
As of 2026, there is no generic version of Xalkori available in the United States. For first-line treatment of ALK-positive NSCLC, newer-generation options like alectinib, brigatinib, or lorlatinib are preferred due to their broader activity. If treating ROS1-positive NSCLC, alternative therapeutic choices instead include lorlatinib and entrectinib.
Warnings:
Xalkori requires regular liver function tests due to warnings for hepatotoxicity, and it must be permanently discontinued if a patient develops drug-related interstitial lung disease or pneumonitis. It can cause cardiac complications such as QT prolongation and bradycardia, requiring ongoing heart rate and ECG monitoring. Severe visual disturbances, including vision loss, have been reported and necessitate drug discontinuation if they occur. Additionally, the medication carries risks for gastrointestinal perforation, embryo-fetal toxicity, and significant interactions with CYP3A inhibitors and inducers.
FAQ (Frequently Asked Questions)
How Much Does Xalkori Cost Without Insurance?
Xalkori costs approximately $20,000–$23,500 per 30-day supply. Through AffordMyPrescriptions, qualifying patients receive Xalkori at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Why Aren't Crizotinib (Xalkori) Regimens First-Line For ALK-Positive NSCLC Anymore?
Crizotinib was the first ALK inhibitor (2011) but has been surpassed by newer-generation ALK inhibitors for first-line therapy. Alectinib, brigatinib, and lorlatinib have better progression-free survival, better CNS penetration (important because ALK-positive NSCLC frequently has brain metastases), and broader activity against ALK resistance mutations. Current NCCN guidelines generally prefer alectinib or other next-generation ALK inhibitors over crizotinib for first-line ALK-positive NSCLC.
Is Crizotinib Still Useful?
Yes — crizotinib retains an important role for ROS1-positive NSCLC (where lorlatinib and entrectinib are alternatives), for ALK-positive anaplastic large cell lymphoma, and for inflammatory myofibroblastic tumor. It also remains an option for ALK-positive NSCLC patients with specific clinical situations or contraindications to newer agents.
Why Is Genomic Testing Necessary Before Xalkori?
Xalkori only works in cancers driven by specific genetic alterations — ALK rearrangements or ROS1 rearrangements (and certain MET alterations in some contexts). Comprehensive genomic profiling of tumor tissue (or sometimes blood) is required to identify the relevant target. Without confirmed ALK or ROS1 alteration, Xalkori would not be effective.
What Should I Watch For With Xalkori?
Visual disturbances (light flashes, blurred vision, floaters) are very common, especially early in treatment — most are mild but report them. Other side effects: nausea, diarrhea, edema, fatigue, decreased appetite, transaminitis. Tell your oncologist about new shortness of breath or cough (pneumonitis), severe vision changes, severe abdominal pain, fast or irregular heartbeat, or symptoms of liver problems (yellow skin, dark urine, abdominal pain).
Can I Get Xalkori Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What If My Application Is Denied?
If denied, we explore alternatives — switching to a newer-generation ALK inhibitor with its own PAP (Alecensa, Alunbrig, Lorbrena), entrectinib (Rozlytrek) for ROS1-positive disease, the manufacturer’s copay program for commercially insured patients, or independent foundations such as the LUNGevity Foundation, ALK Positive, Lung Cancer Research Foundation, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Xalkori, our team may be able to help you access assistance programs designed to make brand specialty ALK/ROS1-targeted lung cancer therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.